Improving Visual Activity Using Gabor Patch Technology in Stargardt Disease: A Retrospective Study

Mincarelli Chiara¹, Gallenga Carla Enrica²*, Colangelo Luigi³, Lobefalo Lucio⁴, Di Carlo Pier Luigi⁴, Nuri Mohamed⁵, Parmeggiani Francesco⁶ and Perri Paolo²

¹CNO Pescara, Orthoptic Service, Pescara, Italy
²Department of Biomedical Surgical Specialistic Sciences, Section Ophthalmology, University of Ferrara, Ferrara, Italy
³Salus Health Center, section Ophthalmology, Battipaglia, Italy
⁴Department of Experimental Surgical Sciences, Section Ophthalmology, G D’Annunzio University, Chieti-Pescara, Italy
⁵Tripoli Eye Hospital, Tripoli, Libya

*Corresponding Author: Gallenga Carla Enrica, Department of Biomedical Surgical Specialistic Sciences, Section Ophthalmology, University of Ferrara, Ferrara, Italy.

Abstract

Gabor patch technology is a non-invasive, patient-specific treatment based on visual stimulation and facilitation of neural connections responsible for vision. The treatment improved BCVA in Stargardt patients. Mean BCVA, for the 10 eyes, has raised from 0.81 (+ 0.17) logMar to 0.49 (+0.07) logMar. Mean ETDRS’ chart lines improvement has been 3.18 +2.05. This improvement appears to be retained for at least 12 months after treatment, consistent with the disease progression.

Keywords: Stargardt Disease; Gabor Patch Technology; Brain Plasticity; Contrast Sensitivity; ABCA4 Gene (1q); Lipofuscin Pisciform-Like Fleks Hyper-Autofluorescent; Retinal Pigmented Epithelium Hypo-Autofluorescent Spot; Dyschromatopsia; Macular Atrophy; Autosomal Recessive Transmission

Introduction

The Stargardt Disease, bilateral symmetric maculopathy, represents the 7% of all retinal hereditary dystrophies with prevalence of 1/10.000; the ABCA4 gene (1q), part of the 7 families ABCA - ABCG of the ATP binding box, is involved in the recessive form, coding for a photoreceptor membrane protein transferring the disc all-trans-retinal to the cytoplasm, where anomalous stable dimers A2PEHE are stored up and via photoreceptor external article phagocytosis transferred to the Pigmented Epithelium (PE) cells where the phagolysosomes can only make a partial degradation to A2E (lipofuscin constituent), detergent molecule toxic for the PE. Photoreceptor degeneration expressing the genetic anomaly is the consequence of PE cell loss; the involvement of macular area is ought to be correlated to the highest cone and rod density in peri- and foveolar zones [1]. Diagnosis is based on the juvenile onset of rapid visual loss stabilizing in a long lasting low vision condition, never ending in blindness, macular granular atrophic pattern with peripapillary and peripheral sparing, pisciform-like flecks of lipofuscin hyper-autofluorescent which comes to a standstill with time but disappearing later on the atrophic macular area and small hypo-autofluorescent spots due to the PE changes, FA choroidal silence, OCT imaging with clivus loss, retinal thinning, loss of photoreceptor line outside the atrophy, multifocal ERG with reduced foveal peak and reduced amplitude of peripheral rings, with a red-green dyschromatopsia as a general rule and a pedigree compatible with autosomal recessive transmission. Waiting for gene therapy, no medical treatment (i.e. isotretinoin, fenretinide, etc.) has been shown to increase the Best Corrected Visual Acuity (BCVA) [2]. Gabor patch technology RevitalVision™ (RV) is a non-invasive, patient-specific treatment based on visual stimulation and facilitation of neural connections.

Improving Visual Activity Using Gabor Patch Technology in Stargardt Disease: A Retrospective Study

connections responsible for vision. The technology involves the use of an internet-based computer generated visual training exercise regime using sets of patient specific stimuli based on Gabor patches, to sharpen contrast sensitivity and, therefore, to improve visual acuity.

Cortical neurons in the visual cortex function as highly specialized image analyzers or filters, responding only to specific parameters of a visual image, such as orientation and spatial frequency, and visual processing involves the integrated activity of many neurons, with interneural interactions effecting both excitation and inhibition [3]. Visual contrast activates neurons involved in vision processing, and neural interactions determine the sensitivity for visual contrast at each spatial frequency, and the combination of neural activities set Contrast Sensitivity Function (CSF) [3,4]. The relationship between neuronal responses and perception are mainly determined by the signal-to-noise ratio (S/N ratio) of neuronal activity, and the brain pools responses across many neurons to average out noisy activity of single cells, thus improving S/N ratio, leading to improved visual performance and acuity [5]. Low vision acts as a major cause of QoL loss [6].

Studies have shown that the noise of individual neurons can be lowered under experimental control by appropriate choice of stimulus conditions and the ability to detect low contrasts can be increased dramatically through control of stimulus parameters [7-10]. This precise control of stimulus conditions leading to increased neuronal efficiency, is fundamental in initiating the neural modifications that are the basis for brain plasticity [11,12]. Brain plasticity (the ability to adapt to changed conditions in acquiring new skills) has been demonstrated in many basic tasks [13-15], with evidence pointing to physical modifications in the adult cortex during repetitive performance [16-18].

The Gabor patch technology has already shown in the last 20 years to specifically promote neuronal interactions, using a set of patient-specific stimuli that improve neuronal efficiency [19,20] and induce improvement of CSF due to a reduction of noise and increase in signal strength [21-24]. As visual perception quality depends both on the input received through the eye and the processing in the visual cortex, this technology compensates for blurred inputs coming from the retina, activating a subjective PRL and by enhancing the neural processing in the visual cortex.

**Technology foundations:** The building block of these visual stimulations is the Gabor patch (Figure 1), which efficiently activates and matches the shape of receptive field in the Visual Cortex.

**Figure 1:** The Gabor etc.

---

The fundamental stimulation-control technique is called “Lateral Masking”, where collinearly oriented flanking Gabors are displayed in addition to the target, central, Gabor patch. The patient is exposed to two short displays in succession, in a random order. The patient’s task is to identify which display contains the target Gabor image (Figure 2). The system provides the patient with audio feedback for an incorrect response. The task is repeated and a staircase is applied until the patient reaches the visual threshold level.

**Figure 2:** Example of Lateral Masking images.

**Home Rehabilitation Protocol:** The Gabor patch RV Treatment System is a software-based, interactive system tailored and continuously adaptive to the individual visual abilities. In the first stage, the subject is exposed to a set of visual perception tasks, aimed to analyze and identify each subject’s neural inefficiencies or deficiencies. Based on this analysis, a treatment plan is initialized, and subject specificity is achieved by administering patient-specific stimuli in a controlled environment (Scheme 1).

**Scheme 1:** The patient at home is connected to and fro via the Cloud to the software-based, interactive system tailored and continuously adaptive to the individual visual abilities (RevitalVision™).
Each session is designed to train, directly and selectively, those functions in the visual cortex, V1 area, via GLG, which were diagnosed to be further enhanced. At each session an algorithm analyzes the patient’s responses and accordingly adjusts the level of visual difficulty to the range most effective for further improvement. Between sessions, the progress of the patient is taken into account by the algorithm for the next session generation. Thus, for each subject an individual training schedule is designed based on the initial state of visual performance, severity of dysfunction and progress in course of treatment. The treatment is applied in successive 30-minute sessions, administered 2 - 3 times a week, a total of approximately 30 - 50 sessions, according to the capacity of improvement perceived at the check-points: every 5 sessions, subject’s visual acuity is tested in order to continuously monitor subject’s progress, stopping at the end of the increasing trend. The average entire treatment duration is around 3 - 4 months.

Results

RV Treatment Group. To evaluate the efficacy of RV Gabor patch Technology in enhancing BCVA in patients with Stargardt disease, 5 Stargardt patients (10 eyes) verified at Ophthalmoscopy/ERG/ FA/ICG/OCT/Ishihara tables, 3 male, 2 female, mean aged 35 (+- 11.11 y.c), caucasians, were selected and informed according to the Helsinki declaration. Investigations included manifest and cycloplegic refraction, LogMAR BCVA.

As for CS Function, results are not included in the analysis in this paper, since no standard detection method has been used.

Exclusion criteria
- Age (<18 > 50 y.o.)
- Other ocular disease impairing the visual axis, neurological disease or mental impairment.

Inclusion criteria
- BCVA stable in the last 6 month in both eyes.

Patients have completed over 30 treatment session. Mean BCVA, for the 10 eyes, has raised from 0.81 (+- 0.17) logMar to 0.49 (+-0.07) logMar. Mean ETDRS’ chart lines improvement has been 3.18 +-2.05 (Table 1, a and b).

<table>
<thead>
<tr>
<th>EYE</th>
<th>BVCA Baseline</th>
<th>BVCA END</th>
<th>Lines ETDRS</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>RE</td>
<td>1.0 LOGMAR</td>
<td>0.4 LOGMAR</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>LE</td>
<td>1.0 LOGMAR</td>
<td>0.4 LOGMAR</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>RE2</td>
<td>0.7 LOGMAR</td>
<td>0.6 LOGMAR</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>LE2</td>
<td>0.7 LOGMAR</td>
<td>0.5 LOGMAR</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>RE3</td>
<td>0.7 LOGMAR</td>
<td>0.5 LOGMAR</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>LE3</td>
<td>0.7 LOGMAR</td>
<td>0.4 LOGMAR</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>RE4</td>
<td>0.7 LOGMAR</td>
<td>0.5 LOGMAR</td>
<td>1.5</td>
<td>Interrupted for pregnancy and breastfeeding</td>
</tr>
<tr>
<td>LE4</td>
<td>0.6 LOGMAR</td>
<td>0.5 LOGMAR</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>RE5</td>
<td>1.0 LOGMAR</td>
<td>0.5 LOGMAR</td>
<td>4.9</td>
<td></td>
</tr>
<tr>
<td>LE5</td>
<td>1.0 LOGMAR</td>
<td>0.5 LOGMAR</td>
<td>4.9</td>
<td></td>
</tr>
</tbody>
</table>

Table 1 a and b: BVCA functional results from baseline are reported and plotted.
Improving Visual Activity Using Gabor Patch Technology in Stargardt Disease: A Retrospective Study

One subject, included in the analysis, has quit the treatment in advance for pregnancy. Results suggest that Gabor patch treatment improves BCVA in Stargardt patients. This improvement appears to be retained for at least 12 months after treatment, consistent with the disease progression. More research is needed with prospective randomized studies with a larger population and for a longer follow up to confirm also the tenure of the positive trend pointed out.

Disclosure
Authors have not financial interest.

Acknowledgement
Mrs Elena Caravaggi, Talshir MT, for technical support.


Bibliography

Improving Visual Activity Using Gabor Patch Technology in Stargardt Disease: A Retrospective Study


Volume 9 Issue 3 March 2018
©All rights reserved by Gallenga Carla Enrica., et al.